LeMaitre Vascular (NASDAQ:LMAT) Upgraded at Zacks Research

Zacks Research upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Several other brokerages also recently weighed in on LMAT. Barrington Research raised their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Citizens Jmp raised their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.80.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $114.81 on Monday. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 45.74, a price-to-earnings-growth ratio of 3.38 and a beta of 0.67. LeMaitre Vascular has a twelve month low of $78.01 and a twelve month high of $118.01. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $103.58 and a two-hundred day moving average of $91.98.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same period last year, the firm earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is 39.84%.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the sale, the insider owned 6,677 shares in the company, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is owned by company insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its position in shares of LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after purchasing an additional 1,735 shares during the period. AQR Capital Management LLC grew its position in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after purchasing an additional 539 shares during the period. Millennium Management LLC grew its position in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.